Journal of Cancer Immunology

Sanjay K. Srivastava

Department of Immunotherapeutics and Biotechnology

Texas Tech University Health Sciences Center

USA

Editor-in-Chief

Biography

Dr. Srivastava is currently a University Distinguished Professor and Chairman of the Department of Immunotherapeutics and Biotechnology at Texas Tech University Health Sciences Center (TTUHSC), Abilene, Texas, specializing in Cancer Biology, Chemoprevention and Cancer Therapeutics. In addition, he is the Associate Dean for Graduate Program in Pharmaceutical Sciences and Biotechnology. Dr. Srivastava also holds James A ‘Buddy’ Davidson Endowed Professorship in Pharmacology and Oncology. He served as an Associate Dean for Research for 6 years at TTUHSC. He was instrumental in bringing the Ph.D. program to Abilene campus. Prior to his arrival at TTUHSC in 2007, Dr. Srivastava served as an Assistant Professor in the Department of Pharmacology, University of Pittsburgh School of Medicine and was a full member of the University of Pittsburgh Cancer Institute. He did his post-doctoral studies from the University of Texas Medical Branch at Galveston, Texas. Dr. Srivastava’s current research is focused on repurposing drugs for melanoma, brain cancer, breast cancer, pancreatic cancer, and ovarian cancer, and is funded by grants from the National Cancer Institute, NIH. He has authored more than 150 research articles, several book chapters and is the Editor of three books. He also holds several patents and received numerous awards. Dr. Srivastava is in the editorial board of several journals and is the member of societies including AACR, SOT, AAAS and AAPS. He serves in the grant review panels of National Institute of Health (NIH), Department of Defense and other agencies. His research work has been featured by various news agencies.

Research Interest

Cancer chemoprevention, drug resistance and therapeutics. Discovery of novel drug targets (STAT-3, NF-kB, HER2, MCL-1, AKT/FOXO, GLI1/2) and their signaling pathways and drug leads such as capsaicin, piperlongumine, penfluridol, isothiocyanates, diindolylmethane, panabinostat and vemurafinib in pancreatic, ovarian, breast, melanoma and brain cancer. Environmental carcinogen-induced cell signaling pathways, molecular carcinogenesis, and molecular toxicology. Repurposing existing drugs (penfluridol, pimozide, pimavanserin, halicin, moxidectin and atovaquone) for cancer treatment.